|Bid||0.0000 x 1000|
|Ask||0.0000 x 800|
|Day's Range||1.1200 - 1.1900|
|52 Week Range||1.0600 - 8.1400|
|Beta (5Y Monthly)||1.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 29, 2023 - Apr 03, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.08|
Viewing insider transactions for Taysha Gene Therapies, Inc.'s ( NASDAQ:TSHA ) over the last year, we see that insiders...
Type B end-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) provided additional clarity for TSHA-120 for the treatment of giant axonal neuropathy (GAN) ultra-rare disease program - FDA acknowledged MFM32 as an acceptable endpoint with a recommendation to dose additional patients in a double-blind, placebo-controlled design to support Biologics License Application (BLA) submission Organizational and business review by new management with operational, structural and personnel change
State officials have terminated an incentive agreement for a Texas-based biotech that had planned to invest $75 million in a manufacturing facility in Durham. The state's Economic Investment Committee, part of the North Carolina Department of Commerce, voted unanimously Tuesday to terminate a package awarded to Taysha Gene Therapies (Nasdaq: TSHA) in late 2020. The vote was in response to a letter the department received from the company requesting withdrawal from the state's Job Development Investment Grant program.